Kinnate Biopharma, Inc. is a precision oncology company advancing a pipeline of therapeutics to treat patients with genomically defined vulnerabilities. Kinnate's focus is on the design and development of selective small molecules with the mission to provide the right drug to the right patient. Headquartered in San Diego, CA, the Kinnate team comprises oncology experts, each with decades of experience developing small molecule therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/19 | $74,500,000 | Series B |
Eshelman Ventures Foresite Capital Nextech Invest OrbiMed Advisors Vida Ventures | undisclosed |
| 08/27/20 | $98,000,000 | Series C |
Boxer Capital Fidelity Management & Research Company Foresite Capital Janus Henderson Investors Logos Capital Nextech Invest OrbiMed Advisors RA Capital Management  Surveyor Capital Venrock Healthcare Partners Viking Global Investors | undisclosed |
